Brokerages Expect Glaukos Corp (GKOS) Will Post Earnings of -$0.01 Per Share
Brokerages forecast that Glaukos Corp (NYSE:GKOS) will post ($0.01) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Glaukos Corp’s earnings, with the lowest EPS estimate coming in at ($0.07) and the highest estimate coming in at $0.06. Glaukos Corp reported earnings of $0.03 per share during the same quarter last year, which would suggest a negative year over year growth rate of 133.3%. The business is expected to announce its next quarterly earnings results after the market closes on Tuesday, November 7th.
On average, analysts expect that Glaukos Corp will report full-year earnings of ($0.02) per share for the current fiscal year, with EPS estimates ranging from ($0.16) to $0.13. For the next year, analysts expect that the business will report earnings of $0.17 per share, with EPS estimates ranging from ($0.16) to $0.55. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Glaukos Corp.
A number of research analysts recently issued reports on GKOS shares. Zacks Investment Research lowered shares of Glaukos Corp from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 12th. BidaskClub lowered shares of Glaukos Corp from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Roth Capital lowered their target price on shares of Glaukos Corp from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $56.00 target price on shares of Glaukos Corp in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $48.57.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/05/brokerages-expect-glaukos-corp-gkos-will-post-earnings-of-0-01-per-share.html.
Glaukos Corp (NYSE GKOS) opened at $36.01 on Friday. Glaukos Corp has a 12 month low of $28.72 and a 12 month high of $52.49. The stock has a market cap of $1,239.97, a price-to-earnings ratio of 327.36 and a beta of 1.25.
In other Glaukos Corp news, CEO Thomas William Burns sold 1,212 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $41.25, for a total value of $49,995.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Orbimed Advisors Llc sold 325,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $37.93, for a total transaction of $12,327,250.00. The disclosure for this sale can be found here. Insiders sold a total of 980,200 shares of company stock worth $37,900,263 over the last 90 days. Company insiders own 16.40% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its position in Glaukos Corp by 93.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Glaukos Corp by 740.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after acquiring an additional 3,118 shares during the period. Prudential Financial Inc. bought a new position in shares of Glaukos Corp during the 1st quarter worth about $204,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Glaukos Corp during the 2nd quarter worth about $262,000. Finally, UBS Asset Management Americas Inc. bought a new position in shares of Glaukos Corp during the 2nd quarter worth about $274,000.
About Glaukos Corp
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp and related companies with MarketBeat.com's FREE daily email newsletter.